DE2214229A1 - Impfstoffpräparat mit Adjuvans - Google Patents
Impfstoffpräparat mit AdjuvansInfo
- Publication number
- DE2214229A1 DE2214229A1 DE19722214229 DE2214229A DE2214229A1 DE 2214229 A1 DE2214229 A1 DE 2214229A1 DE 19722214229 DE19722214229 DE 19722214229 DE 2214229 A DE2214229 A DE 2214229A DE 2214229 A1 DE2214229 A1 DE 2214229A1
- Authority
- DE
- Germany
- Prior art keywords
- vaccine
- polysaccharide
- oxidized
- adjuvant
- coam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 title claims description 68
- 239000002671 adjuvant Substances 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title claims description 15
- 229920001282 polysaccharide Polymers 0.000 claims description 24
- 239000005017 polysaccharide Substances 0.000 claims description 24
- 150000004804 polysaccharides Chemical class 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 8
- 229920000856 Amylose Polymers 0.000 claims description 6
- 229920000945 Amylopectin Polymers 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 5
- 229920002230 Pectic acid Polymers 0.000 claims description 5
- 239000010318 polygalacturonic acid Substances 0.000 claims description 5
- 229920002907 Guar gum Polymers 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 239000000783 alginic acid Substances 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 229960001126 alginic acid Drugs 0.000 claims description 4
- 150000004781 alginic acids Chemical class 0.000 claims description 4
- 235000010417 guar gum Nutrition 0.000 claims description 4
- 150000001447 alkali salts Chemical class 0.000 claims description 3
- 230000000890 antigenic effect Effects 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 235000010980 cellulose Nutrition 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 2
- 150000002772 monosaccharides Chemical class 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- -1 alkali metal salt Chemical class 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 201000006747 infectious mononucleosis Diseases 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000002255 vaccination Methods 0.000 description 8
- 241000700198 Cavia Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 229920001577 copolymer Polymers 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 230000000240 adjuvant effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229960003971 influenza vaccine Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000012646 vaccine adjuvant Substances 0.000 description 3
- 229940124931 vaccine adjuvant Drugs 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 241001474374 Blennius Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 229920002201 Oxidized cellulose Polymers 0.000 description 1
- 206010034107 Pasteurella infections Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- TWCGLLOGIJJUGJ-DAGMQNCNSA-N ethyl 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboximidate Chemical compound N1=C(C(=N)OCC)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 TWCGLLOGIJJUGJ-DAGMQNCNSA-N 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940107304 oxidized cellulose Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US00128530A US3839555A (en) | 1971-03-26 | 1971-03-26 | Vaccine adjuvant and method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2214229A1 true DE2214229A1 (de) | 1972-09-28 |
Family
ID=22435777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19722214229 Pending DE2214229A1 (de) | 1971-03-26 | 1972-03-23 | Impfstoffpräparat mit Adjuvans |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US3839555A (enExample) |
| BE (1) | BE781028R (enExample) |
| CA (1) | CA980251A (enExample) |
| CY (1) | CY840A (enExample) |
| DE (1) | DE2214229A1 (enExample) |
| FR (1) | FR2130132B2 (enExample) |
| GB (1) | GB1327740A (enExample) |
| IN (1) | IN139166B (enExample) |
| NL (1) | NL7202698A (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4122906A1 (de) * | 1990-07-10 | 1992-02-13 | Charite Med Fakultaet | Impfstoffe gegen virale antigene und verfahren zu ihrer herstellung |
| DE4141970A1 (de) * | 1991-12-16 | 1993-06-17 | Charite Med Fakultaet | Kombinationsimpfstoff gegen aids, bilharziose und tuberkulose und verfahren zu seiner herstellung |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4243663A (en) * | 1976-06-25 | 1981-01-06 | Ichiro Azuma | Glycolipid compositions for transplanted tumor immunotherapy |
| FR2590674B1 (fr) * | 1985-11-25 | 1989-03-03 | Inst Nat Sante Rech Med | Nouveaux reactifs de diagnostic |
| US4761281A (en) * | 1986-04-22 | 1988-08-02 | Immunomed Corporation | Vaccine from Dirofilaria extracts |
| WO2005039597A2 (en) | 2003-10-24 | 2005-05-06 | N.V. Nutricia | Immunemodulating oligosaccharides |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1137540A (en) * | 1966-12-20 | 1968-12-27 | Nat Res Dev | Improvements relating to the treatment of hypocalcaemia |
| CA928218A (en) * | 1969-06-17 | 1973-06-12 | Recherche Et Industrie Therapeutiques R.I.T. | Antiinfectious compositions and process for their preparation |
-
1971
- 1971-03-26 US US00128530A patent/US3839555A/en not_active Expired - Lifetime
-
1972
- 1972-03-01 NL NL7202698A patent/NL7202698A/xx not_active Application Discontinuation
- 1972-03-08 FR FR7207982A patent/FR2130132B2/fr not_active Expired
- 1972-03-16 CA CA137,229A patent/CA980251A/en not_active Expired
- 1972-03-22 BE BE781028A patent/BE781028R/xx active
- 1972-03-22 CY CY840A patent/CY840A/xx unknown
- 1972-03-22 GB GB1344472A patent/GB1327740A/en not_active Expired
- 1972-03-23 DE DE19722214229 patent/DE2214229A1/de active Pending
-
1973
- 1973-09-07 IN IN2053/CAL/73A patent/IN139166B/en unknown
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4122906A1 (de) * | 1990-07-10 | 1992-02-13 | Charite Med Fakultaet | Impfstoffe gegen virale antigene und verfahren zu ihrer herstellung |
| DE4122906C2 (de) * | 1990-07-10 | 1998-02-19 | Charite Med Fakultaet | Impfstoffe gegen virale oder bakterielle Antigene und Verfahren zu ihrer Herstellung |
| DE4141970A1 (de) * | 1991-12-16 | 1993-06-17 | Charite Med Fakultaet | Kombinationsimpfstoff gegen aids, bilharziose und tuberkulose und verfahren zu seiner herstellung |
| DE4141970C2 (de) * | 1991-12-16 | 1998-02-19 | Charite Med Fakultaet | Kombinationsimpfstoff gegen AIDS, Bilharziose und Tuberkulose und Verfahren zu seiner Herstellung |
Also Published As
| Publication number | Publication date |
|---|---|
| CA980251A (en) | 1975-12-23 |
| NL7202698A (enExample) | 1972-09-28 |
| US3839555A (en) | 1974-10-01 |
| GB1327740A (en) | 1973-08-22 |
| CY840A (en) | 1976-09-10 |
| IN139166B (enExample) | 1976-05-15 |
| FR2130132A2 (enExample) | 1972-11-03 |
| BE781028R (fr) | 1972-09-22 |
| FR2130132B2 (enExample) | 1975-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69128782T2 (de) | Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff | |
| DE3712767C2 (enExample) | ||
| DE3787663T2 (de) | Impfstofformulierung. | |
| DE69319728T2 (de) | Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten | |
| DE69520376T2 (de) | Ein hydrophobisches sulfolipidisches polysaccharid enthaltendes adjuvans für impfstoffe | |
| DE2362121C2 (de) | Adjuvans-Zusammensetzungen für Antigen-Präparate | |
| DE69634024T2 (de) | Adjuvans für vitale Impfstoffe | |
| DE69623072T2 (de) | Impfstoffzusammensetzung für Säugetiere enthaltend Squalen oder Squalan, Phospholipid und ein Tensid als Adjuvans | |
| EP1265633A2 (de) | Adjuvans für vakzinen | |
| EP0363835B1 (de) | Verwendung von Zink- oder Eisenhydroxid zur Adjuvierung von Antigenlösungen und auf diese Weise adjuvierte Antigenlösungen | |
| DD297331A5 (de) | Verfahren zur herstellung eines impfstoffes | |
| DE60019726T2 (de) | Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans | |
| EP0230264B1 (de) | Nasal applizierbares Arzneimittel, Verfahren zu seiner Herstellung und seine Verwendung | |
| DE2214229A1 (de) | Impfstoffpräparat mit Adjuvans | |
| DE2643641A1 (de) | Antigene praeparate und verfahren zu ihrer herstellung | |
| EP0445710B1 (de) | Verwendung von Zink-Calciumhydroxid, Lecithin und PAO zur Adjuvierung von Antigenlösungen und auf diese Weise adjuvierte Antigenlösungen | |
| DE1924304B2 (de) | Diäthylaminoäthyldextran (DEAE-D) als Adjuvans für Impfstoffe zur aktiven Immunisierung von Säugetieren | |
| EP0121752A2 (de) | Verfahren zur Adjuvierung von Vaccinen | |
| DE3122669A1 (de) | "verfahren zur herstellung von neuen mutanten von herpes simplex-viren typ 1 und typ 2" | |
| DE2010788A1 (de) | Wasserunlösliche Substanzen mit Antigenwirkung und Verfahren zu ihrer Herstellung | |
| DE2262427C3 (de) | Immunostimulierendes Mittel | |
| DE3446515A1 (de) | Oeladjuvierte vaccine und verfahren zu ihrer herstellung | |
| DE2225548C3 (de) | Intravenös verträglicher Impfstoff gegen Staupe- und Hepatite contagiosa canis | |
| DE2134930A1 (de) | Antigene Extrakte | |
| DE602004004768T2 (de) | Subkutan verabreichte impfstoffzusammensetzungen auf gangliosidbasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHW | Rejection |